English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In vivo assessment of cancer and precise location of altered tissues atinitial stages of molecular disorders are important diagnostic challenges.Positronium is copiously formed in the free molecular spaces in the patient'sbody during positron emission tomography (PET). The positronium properties varyaccording to the size of inter- and intramolecular voids and the concentrationof molecules in them such as, e.g., molecular oxygen, O2; therefore,positronium imaging may provide information about disease progression duringthe initial stages of molecular alterations. Current PET systems do not allowacquisition of positronium images. This study presents a new method thatenables positronium imaging by simultaneous registration of annihilationphotons and deexcitation photons from pharmaceuticals labeled withradionuclides. The first positronium imaging of a phantom built from cardiacmyxoma and adipose tissue is demonstrated. It is anticipated that positroniumimaging will substantially enhance the specificity of PET diagnostics.

Positronium imaging with the novel multiphoton PET scanner